Please login to the form below

Not currently logged in
Email:
Password:

follicular lymphoma

This page shows the latest follicular lymphoma news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene’s Revlimid gets a win in late-stage lymphoma

The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed ... An earlier read-out in

Latest news

  • Another R&D flop for Incyte, but Jakafi keeps delivering Another R&D flop for Incyte, but Jakafi keeps delivering

    Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

  • NHS chief pledges CAR-T support, but asks for pricing restraint NHS chief pledges CAR-T support, but asks for pricing restraint

    Kite’s CAR-T Yescarta (axicabtagene ciloleucel) was the first to be submitted for approval in Europe and is being reviewed by the EMA for diffuse large B-cell lymphoma (DLBCL), ... primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    The UK’s National Institute for Health and Care Excellence (NICE) has recommended Roche’s Gazyvaro as a first-line treatment for lymphoma patients, reversing its earlier stance on the drug. ... Last September the cost-effectiveness watchdog turned

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

  • Roche's Actemra/RoActemra receives new European approval Roche's Actemra/RoActemra receives new European approval

    Gazyvaro approved for advanced follicular lymphoma. Meanwhile, the European Commission has also licensed Roche’s Gazyvaro (obinutuzumab) for patients with previously untreated advanced follicular lymphoma. ... with follicular lymphoma who did not

More from news
Approximately 2 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics